Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.8201 -0.0379 (-4.42%)
Streaming Delayed Price Updated: 10:12 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death Intellectual Property
News headline image
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $2.25 Million Public Offering for Clearmind Medicine Inc. (NASDAQ:CMND)
Via ACCESSWIRE
News headline image
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
News headline image
Clearmind Medicine Closes US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering ↗
Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies 
Via Benzinga
News headline image
Nasdaq Surges 100 Points; First Wave BioPharma Shares Spike Higher ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.93% to 34,898.47 while the NASDAQ rose 0.75% to 13,917.44.... 
Via Benzinga
Topics Stocks
News headline image
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi. 
Via Benzinga
News headline image
Crude Oil Rises Sharply; BIOLASE Shares Plunge ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.61% to 34,784.94 while the NASDAQ rose 0.71% to 13,911.78. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Clearmind Medicine Stock Is Getting Hammered Today ↗
Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 53% to $0.18 Thursday morning after the company announced pricing of a $2.25 million public offering. The offering is expected to close... 
Via Benzinga
News headline image
Dow Jumps Over 200 Points; US Producer Prices Rise In August ↗
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.71% to 34,820.58 while the NASDAQ rose 0.27% to 13,849.49. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading. 
Via Benzinga
News headline image
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
News headline image
Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed ↗
Specialty clinical-stage biopharma company SciSparc Ltd. (NASDAQ: SPRC) has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with... 
Via Benzinga
News headline image
Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program ↗
Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical... 
Via Benzinga
News headline image
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
News headline image
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio ↗
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of... 
Via Benzinga
News headline image
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome ↗
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd. 
Via Benzinga
News headline image
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period ↗
Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of... 
Via Benzinga
News headline image
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.